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SUMMARY
Purpose: We investigated the cumulative probability of
seizure remission and relapse in an adult population with
drug-resistant epilepsy and frequent seizures. In addition,
we determined clinical predictors of remission and
relapse in this population.
Methods: In 2003, we identified 246 patients at a single
center with drug-resistant epilepsy defined as at least one
seizure per month and failure of at least two antiepileptic
drugs. These patients were followed prospectively (cohort
design). We examined the cumulative probability of sei-
zure remission and relapse in this population usingKaplan-
Meier methodology. Clinical predictors of remission and
relapsewere alsoevaluatedusingCox regression analysis.
Key Findings: The estimated cumulative probability of
12-month seizure remission was 34.6% at 7 years in the
entire population and 33.4% when limited to those with-
out surgery. The risk for relapse after a 12-month period
of seizure remission was 71.2% at 5 years. Negative pre-
dictors of seizure remission included developmental
delay, symptomatic generalized epilepsy syndrome, dura-
tion of intractability, and number of antiepileptic drugs
failed. Localization-related epilepsy was the only negative
predictor of relapse.
Significance: Among patients with drug-resistant epi-
lepsy, 5% per year enter seizure remission even with a fol-
low-up of 6 years. However, a substantial proportion of
these patients relapse after the first year following a
remission. The large proportion of patients entering a sig-
nificant remission gives these patients hope; however,
caution should be advised when discussing the likelihood
of future seizures.
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Epilepsy is a common neurologic disorder with a preva-
lence of 0.4–1% (Duncan et al., 2006). Previous studies
have estimated that between 20% and 40% of patients
have drug-resistant epilepsy (DRE) (Annegers et al., 1979,
Elwes et al., 1984; Shafer et al., 1988; Anonymous, 1992;
Cockerell et al., 1995; Sillanpaa et al., 1998; Kwan &
Brodie, 2000; Lindsten et al., 2001). Patients in this group
are affected in multiple ways, including decreased educa-
tional attainment, employment, and marriage (Sperling,
2004). Furthermore, they are at increased risk for mortality
and psychiatric comorbidities, and are unable to drive
(Sperling, 2004). Clearly, DRE has a major impact on the
lives of these patients.
Until recently, there had been only a few studies focusing
on DRE, including those of Huttenlocker, Silanpaa, and
Berg, all focusing on children (Huttenlocher &Hapke, 1990;
Sillanpaa, 1993; Berg et al., 1996; Sillanpaa et al., 1998;
Berg et al., 2006, 2009). Silanpaa et al. investigated predic-
tors of long-term remission in children and found that rapid
response to therapy and idiopathic epilepsy were associated
with remission (Sillanpaa et al., 1998). Berg et al. per-
formed a case–control study that identified remote symp-
tomatic epilepsy, younger age at onset, and status
epilepticus as predictors of intractability (Berg et al., 1996).
In a separate analysis, Berg et al. found that idiopathic epi-
lepsy and lower seizure frequency were predictive of a
remission after failure of two antiepileptic drugs (AEDs)
(Berg et al., 2009). Although long-term predictors of epi-
lepsy have been studied in pediatric populations for years,
study of adult populations has lagged behind.
More recently there have been a few adult studies investi-
gating the course of DRE. In 2007 Luciano et al. followed a
retrospective cohort of 155 patients who were seizing at
least once per month and had a history of epilepsy of at least
5 years (Luciano & Shorvon, 2007). After a median of
19 months, 28% of these patients became seizure free for at
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least 12 months following the addition of an AED. Predic-
tors of seizure remission included less than five previous
AEDs, idiopathic epilepsy, and a duration of epilepsy of less
than 10 years. In 2007, our group reported on 246 patients
with DRE defined as a seizure frequency exceeding one per
month and failure of more than two AEDs (Callaghan et al.,
2007). We found that 5% per year had a 6 month or greater
seizure-free period over 3 years of observation. Negative
predictors of seizure remission included number of AEDs
failed, younger age of intractability, developmental delay,
and a history of status epilepticus. In 2008, Choi et al.
described 187 patients using the same definition of DRE as
used by our group, (Callaghan et al., 2007) and reported 4%
per year achieving 1 year or greater seizure remission (Choi
et al., 2008). All of these studies showed a higher than
expected cumulative probability for seizure remission in
DRE compared with Kwan and Brodie’s report (2000),
which showed that only 11% of patients that failed the first
AED secondary to lack of efficacy become seizure free
(Kwan & Brodie, 2000). Despite the lack of consensus on
the definition of DRE, similar factors emerged as clinical
predictors of remission in these later studies.
The studies described raise as many questions as they
answer. Seizure ‘‘remission’’ was usually defined as one or
more years of seizure freedom, with the patient remaining
seizure free at the time of the last visit. Although this can be
a meaningful length of time in the course of epilepsy, it does
not necessarily translate to the ultimate goal of epilepsy
therapy, which is a long-term or even permanent seizure
freedom. In addition, prior studies did not address whether
these patients went on to have sustained seizure remissions.
Only Choi et al. (Choi et al., 2008) commented on relapse
rate, but the duration of follow-up was short. Furthermore,
studies to date did not identify risk factors for relapse in
patients with DRE who enter a seizure remission, and the
three studies following adult cohorts with DRE have had
only 18 months to 4 years of follow-up to date. Therefore,
the purpose of this study is to investigate the cumulative
probability for remission and relapse in a DRE population
followed prospectively over a longer time period. Because
DRE causes significant morbidity and mortality, there are
important unanswered questions to address, regarding when
to try additional medications, advocate surgery or vagal
nerve stimulators, and when to advise patients that driving
is safe. Insight into the natural history of DRE is the first
step toward providing these answers.
Methods
In 2003, we identified a retrospective cohort of 246
patients who met the following definition of DRE: (1)
Greater than or equal to one seizure per month for the
3 months prior to the index date and (2) failed greater than
or equal to two AEDs prior to the index date (Callaghan
et al., 2007). All patients had been seen in 2000 (index date)
at the University of Pennsylvania Epilepsy Center and had
at least one follow-up visit. Since that time we have fol-
lowed this group prospectively through 2006. We initially
documented demographics as well as seizure type, epilepsy
syndrome, etiology of epilepsy, presence of developmental
delay (IQ <70), any history of status epilepticus (seizures
lasting greater than 30 min), age of onset, age of intractabil-
ity, previous number of AEDs failed, electroencephalogra-
phy (EEG) and magnetic resonance imaging (MRI) results,
seizure frequency at index, and number of years at the epi-
lepsy center. During the subsequent follow-up, we have
documented all changes in AEDs including dose changes
and reason for failure, and all seizure remissions
>12 months including seizure remission at the time of the
last visit. Relapse was defined as recurrence of any seizure
including simple partial seizures (auras) after becoming sei-
zure free for greater than 1 or 2 years. Interventions were
recorded such as vagal nerve stimulators, surgery including
temporal lobectomy, intracranial monitoring, and deep
brain stimulation. The number of AEDs tried since the index
date, as well as the date and status at last follow-up were
obtained. Follow-up methods included chart review, and,
for those not seen within the past year, search of the
National Social Security death index prior to additional
attempts at direct contact using last known phone number.
Statistical analysis
Kaplan-Meier analyses were used to estimate the cumula-
tive probability for a 12 month and 24 month or greater sei-
zure remission in adults with DRE. Patients were censored
if they died or were lost to follow-up. These analyses were
repeated separating the cohort into those with and without
surgery. Surgery was defined as any therapeutic intracranial
surgical intervention, with most being temporal lobecto-
mies. Among those with surgery, the follow-up period
began at the time of surgery, whereas for those without sur-
gery, follow-up began at the index date in 2000. We used
Cox proportional hazards regression to examine predictors
of entering a seizure remission in all patients with DRE.
Factors examined included developmental delay, history of
status epilepticus, epilepsy syndrome, age at onset, duration
of intractability, and number of AEDs failed. Univariate
analyses were conducted and those factors that were statisti-
cally significantly associated with entering a seizure remis-
sion were simultaneously entered into an adjusted model.
Among those patients who achieved a 12 or 24 month or
greater seizure remission, Kaplan-Meier analyses were used
to estimate the cumulative risk for seizure relapse. Patients
were censored if they died or were lost to follow-up. For
these patients, follow-up began at the time of their 12- or
24-month seizure remission. We examined predictors of sei-
zure relapse after a seizure remission using Cox propor-
tional hazards regression. Factors examined as predictors
were the same as those used in the analysis of predictors of
seizure remission.
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Results
In our DRE population, 177 (80.5%) had localization-
related epilepsy, 27 (11%) had symptomatic generalized
epilepsy, 17 (6.9%) had primary generalized epilepsy, and 4
(1.6%) had another epilepsy syndrome (Fig. 1). The mean
and median age of this patient population at the index date
was 40 years, with a range of 12–83 years. Fifty-nine per-
cent of the population was female. The median duration of
epilepsy was 25 years [interquartile range (IQR) 14–36
years], and the median duration of intractability was
18.6 years (IQR 6.8–31.9 years). The median duration of
follow up was 5.9 years (IQR 5.1–7.2 years). The reasons
for drug failure before index date were maximum tolerated
dose in 54% of cases, idiosyncratic reaction in 6.5%, intoler-
able side effect in 19%, and unknown reasons in 21%.
Twenty-four of the patients were deceased at last follow-up.
In addition, 20 patients (8%) were lost to follow-up despite
attempts to contact patients at their last known phone
number.
Outcomes
Remission
Fifty-nine of 246 patients (24.0%) obtained a 12-month
seizure remission. Forty-one patients became seizure free
with medication change, 10 after surgery, and 8 with no sur-
gery or medication change.
The cumulative probabilities of greater than 12-month
seizure freedom among the entire cohort with DRE,
restricted to those without any brain surgery, and those with
surgery are listed in Table 1 (Figs. 2 and 3). The cumulative
probabilities of greater than 24-month seizure freedom
among the entire cohort is also listed in Table 1 (Fig. 1).
Clinical predictors of seizure remission
Several factors were associated with a decreased cumu-
lative probability for a 12 month or greater seizure remis-
sion in unadjusted analysis (Table 2). These included
presence of developmental delay, symptomatic generalized
epilepsy syndrome, longer duration of intractability, and
Figure 1.
Patient Demographics and
Clinical Characteristics.Demo-
graphics and clinical characteristics
of the adult drug-resistant epilepsy
cohort (N = 246).
Epilepsia ILAE
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number of AEDs failed. Neither age at onset nor status
epilepticus was statistically significantly associated with
seizure remission. In adjusted analysis, only the number
of AEDs failed was an independent negative predictor of
seizure remission (Table 2).
Relapse
Thirty-four of the 59 patients who obtained a 12-month
remission had a subsequent relapse. The cumulative risk of
subsequent seizures after a 12-month seizure remission
was 40.1% [95% confidence interval (95% CI) 28.4–
54.4%], 55.7% (95% CI 42.0–70.4%), 58.5% (95% CI
73.0–44.5%), 65.4% (95% CI 50.6–79.7%), and 71.2%
(95% CI 54.7–85.8%) at 1–5 years, respectively (Fig. 3).
The cumulative risk of relapse after a 24-month seizure
remission was 23.6% at year 1 (95% CI 11.3–45.4%),
28.1% at year 2 (95% CI 14.4–50.4%), and 46.7% at year 3
(95% CI 27.5–70.7%) (Fig. 4). All patients that relapsed
had seizures other than just simple partial seizures (auras).
Of the 34 patients who relapsed, 18 (53%) had a second
remission of greater than 12 months. For 8 of these 18
patients, the second remission lasted to the end of follow-
up. Seven of the 18 patients had a second relapse, and 3 had
at least three total relapses.
Clinical predictors of relapse
Relapse was less likely for localization-related epilepsy
(Table 2). Several factors examined that were not statisti-
cally significantly associated with relapse, included devel-
opmental delay, a history of status epilepticus, age at onset,
duration of intractability, and number of AEDs failed.
Effect of medication change on relapse
Of the 59 patients that entered remission, 50.8% had no
subsequent change in their AED regimen, 18.6% had a
decreased dose, and 13.6% had discontinuation of an AED.
In the group that relapsed 55.9% had no change in medica-
tion, 26.5% had a decreased dose, and 5.9% had an AED
discontinued. Similarly, in the group with sustained remis-
sions without relapse, 44.0% had no medication change,
8.0% had a decreased dose, and 24.0% had an AED discon-
tinued. Among the patients who relapsed, 44.1% had a mild
course (1–2 total seizures), 17.6% moderate (<1 seizure per
month), and 26.5% severe (>1 seizure per month). Taken
together, 61.7% of those that relapsed had a lower seizure
frequency than they experienced at study entry.
Discussion
An unexpectedly high proportion of adults meeting our
definition of DRE attained a seizure remission of 12 months
or more (5%/year). This is the same proportion we had
previously shown with only 3 years of follow-up, indicating
Table 1. Cumulative probabilities remission among the entire cohort (12 and 24 months), restricted to those
without any brain surgery, and including only those with surgery
End point Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
12 Month remission 7.0% (4.4–11.2) 12.1% (8.5–17.1) 17.9% (13.4–23.7) 21.9% (16.9–28.1) 27.5% (21.5–34.7) 34.6% (26.4–44.4)
12 Month remission,
no surgery
6.3% (3.7–10.6) 11.5% (7.8–16.7) 16.9% (12.3–22.9) 20.3% (15.2–26.7) 25.2% (19.3–32.5) 33.4% (24.7–44.2)
First remission, surgery 44.7% (27.6–66.4) 44.7% (27.6–66.4) 49.3% (31.5–70.6) – – –
24 Month remission 0.00% 5.3% (3.0–9.3) 8.9% (5.7–13.8) 11.70% (7.9–17.1) 13.90% (9.6–19.8) 22.70% (14.9–33.8)
95% Confidence intervals in parentheses.
A
B
Figure 2.
Time to first seizure remission. Kaplan-Meier curves of
time to 1-year seizure remission (A) and time to 2-year seizure
remission (B).
Epilepsia ILAE
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that this proportion remains stable over a 6-year period
(Callaghan et al., 2007). Therefore, about one third of
patients with DRE can be expected to experience a pro-
longed seizure remission over a 6-year period, a percentage
that is likely to grow over time. Given the fact that this
population was initially seizing at least once per month, a
Table 2. (A) Risk factors for 1 year or greater
remission, (B) Risk factors for relapse after 1 year or
greater remission
Variable
n
(% remission)
RR
(95% CI)
Adjusted RR
(95% CI)
(A)
Developmental delay
Yes 69 (14.5) 0.45 (0.23–0.90) 0.60 (0.29–1.2)
No 177 (27.7) 1.0 (Referent) 1.0 (Referent)
Status epilepticus NA
Yes 39 (12.8) 0.46 (0.18–1.2)
No 207 (26.1) 1.0 (Referent)
Epilepsy syndrome NA
Localization-
related
198 (25.8) 0.98 (0.14–7.1)
Symptomatic
generalized
27 (3.7) 0.118 (0.007–1.9)
Primary
generalized
17 (35.3) 1.4 (0.16–11.4)
Other 4 (25.0) 1.0 (Referent)
Age at onset NA
<15 years 151 (25.8) 1.2 (0.70–2.1)
£15 years 95 (21.1) 1.0 (Referent)
Duration of intractability
‡10 years 171 (19.9) 0.52 (0.31–0.88) 0.76 (0.43–1.3)
<10 years 75 (33.3) 1.0 (Referent) 1.0 (Referent)
Number of AEDs failed
‡6 145 (15.9) 0.39 (0.23–0.66) 0.46 (0.27–0.80)
<6 101 (35.6) 1.0 (Referent) 1.0 (Referent)
Variable n (% relapse) RR (95% CI)
(B)
Developmental delay
Yes 10 (50.0) 0.85 (0.33–2.2)
No 49 (55.1) 1.0 (Referent)
Status epilepticus
Yes 5 (80.0) 1.57 (0.55–4.5)
No 54 (51.9) 1.0 (Referent)
Epilepsy syndrome
Localization-related 51 (51.0) 0.31 (0.04–2.3)
Symptomatic generalized 1 (100.0) 1.0 (0.11–9.0)
Primary generalized 6 (66.7) 0.74 (0.05–11.9)
Other 1 (100.0) 1.0 (Referent)
Age at onset
<15 years 39 (66.1) 0.77 (0.38–1.6)
‡15 years 20 (60.0) 1.0 (Referent)
Duration of Intractability
‡10 years 34 (58.8) 1.2 (0.57–2.4)
<10 years 25 (48.0) 1.0 (Referent)
Number of AEDs failed
‡6 23 (69.6) 1.8 (0.90–3.6)
<6 36 (44.4) 1.0 (Referent)
RR, relative risk.
Figure 3.
Time to first seizure remission in the surgery group.
Kaplan-Meier curve of time to 1-year seizure remission in the
surgery group (any intracranial surgical intervention, with most
being temporal lobectomies) starting from the surgery date.
Epilepsia ILAE
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B
Figure 4.
Time to relapse after a significant seizure remission.
Kaplan-Meier curves of time to relapse after 1-year seizure
remission (A) and after 2-year seizure remission (B).
Epilepsia ILAE
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12-month seizure remission is a meaningful change. It is
important for patients with DRE to be aware that there is a
substantial chance of a prolonged seizure remission even
though permanent seizure freedom is much less likely. The
short-term prognosis for patients with frequent seizures is
perhaps not as bleak as previously believed.
However, a large percentage of patients that achieve a
12-month or greater seizure remission eventually relapse
(71% at 6 years after onset of the remission). This is also
true after a 24 month or greater seizure remission (47% at
4 years after onset of the remission). As a result, epileptolo-
gists must use caution when discussing seizure prognosis in
this patient population, a particularly important consider-
ation when addressing the question of when patients should
return to driving. Currently, in most states, patients are
restricted from driving for 6–12 months following a seizure.
However, at least in this drug-refractory population, many
relapses occur well after a 1-year seizure free period. In fact,
the relapse curve does not start to level off until approxi-
mately 2 to 3 years after the patient’s last seizure. It is pos-
sible that a longer time without driving is necessary for the
previously treatment-resistant patient to avoid potentially
devastating consequences. The relapse rate also raises the
question of when a patient with DRE should be considered
cured, as our findings suggest that even multiple years after
a last seizure there is still a significant risk of recurrence.
Although we were unable to systematically address AED
discontinuation, it would appear prudent to continue therapy
in patients who have had a 1-year seizure remission, since
more than half of them have not had their last lifetime
seizure.
Interestingly, the high probability of relapse found in this
study was also seen by Berg et al. (Berg et al., 2009). They
followed an incident cohort of 128 children with drug-
refractory epilepsy defined as failure of two AEDs due to
lack of efficacy and no remission greater than 1 year by the
time of the second AED failure. In their population, 68% of
their patients experienced a relapse after a 12-month remis-
sion after a median follow-up of 10 years in comparison to
the 58% seen in our study after 6 years. However, they
reported a probability of a 1-year remission at 5 years of
47% compared to 22% in our prevalence cohort. The con-
trasting probability of remission is likely due to several dif-
ferences in these two studies, including the different age
distributions (children versus adults), type of cohorts (inci-
dent versus prevalence), and definition of drug-resistant epi-
lepsy (>1 seizure per year versus >1 seizure per month).
Similarly, Schiller et al. described a cohort of 256 patients
who had a greater than 1 year remission and reported a sub-
stantial degree of relapse when followed for 5 years
(40.2%) (Schiller, 2009). The major difference between
this cohort and ours is that we included only those with
refractory epilepsy at baseline having one seizure per
month, whereas Schiller et al. included all patients with
epilepsy. Despite these substantial differences, all of these
studies agree that a substantial number of patients with
drug-refractory epilepsy experience significant remissions,
but that a large proportion of these patients also relapse.
The present study found four factors associated with a
decreased risk for a 12-month or greater seizure remission,
but no factors were associated with subsequent relapse. The
four factors associated with remission were developmental
delay, symptomatic generalized epilepsy, duration of intrac-
tability, and number of AEDs failed. However, only number
of AEDs failed remained a statistically significant predictor
in the adjusted model. This result is not surprising given the
work of Schiller and Najjar, who discovered that remission
is a function of the number of past AEDs failed in a cohort
of all patients with epilepsy undergoing new AED therapy
(Schiller & Najjar, 2008). Our data indicate that this is also
a predictor of remission in a drug-resistant cohort. These
results are in agreement with our previous study in the same
cohort where follow-up was shorter and a more brief sei-
zure-free period defined remission, with the exception that
the prior study showed that a history of status epilepticus
was associated with a reduced likelihood of remission
(Callaghan et al., 2007). In the current analysis, there was a
trend for a history of status to be associated with a reduced
likelihood of remission (rate ratio 0.46), which was also
seen as a predictor of intractability by Berg et al. (Berg
et al., 1996). Our study suggests that prior studies are not
actually identifying predictors of long-term treatment suc-
cess, since those in the ‘‘seizure free’’ group at the end of the
observation period included many who had been seizure
free for <3 years, and a substantial number of those would
be expected to relapse in future years. The lack of predictors
associated with relapse was surprising given that we
expected that some of the same factors that were associated
with remission would also impact relapse. However, the rel-
atively small numbers in the relapse group may have limited
our ability to detect these associations.
The reasons for relapse in this population do not appear to
be limited to medication withdrawal or dose reductions.
Approximately the same number of patients with sustained
remissions (32%) had medication changes as those who sub-
sequently relapsed (32%). Therefore, there are likely fac-
tors, other than medication changes, that result in relapse
after a significant remission. Among patients who relapsed,
the majority (62%) had a lower seizure frequency than they
experienced at study entry. This emphasizes that an impor-
tant percentage of patients in this refractory population have
a significant improvement in their seizure control even if
they do not have a sustained remission.
There are limitations to our study. The sample size makes
definitive conclusions about the clinical predictors of remis-
sion and relapse difficult. Many of these predictors barely
met statistical significance and very few of them continued
to meet criteria for significance in adjusted models. In addi-
tion, the lack of association between certain variables and
remission or relapse does not mean that none exists. Further-
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more, we were unable to evaluate predictors of longer term
remission such as greater than 5 years given the length of
follow-up. On the other hand, our adult DRE cohort contin-
ues to be the largest in the literature. Furthermore, many of
these clinical predictors have been confirmed in the few
other adult studies or in pediatric populations. Another limi-
tation is that we studied many different variables, which
increases the likelihood of an association by chance. More-
over, we chose a definition of DRE prior to the new Interna-
tional League Against Epilepsy (ILAE) definition (Kwan
et al., 2010). This new definition agrees with our definition
with respect to number of AEDs failed, although it adds
rigor in regard to the definition of AED failure. Of greater
importance, the new definition does not include a seizure
frequency requirement such as the one seizure per month, as
used in our study. If we had not used this requirement, the
study would have needed to be even longer in duration. As a
consequence of these differences in definition, the general-
izability of our results to a refractory population with less
frequent seizures is unclear. However, the advantage of
establishing an initial one seizure per month or greater sei-
zure frequency is that we could confirm that a 1-year sei-
zure-free interval was a meaningful remission for every
patient, whereas if such a seizure frequency was not estab-
lished, this might not be the case. The new ILAE definition
of treatment response requires no seizures for three times
the prior interseizure interval. Therefore, the prior intersei-
zure interval must be known to assess outcome. Another
limitation is that we do not have information on drug adher-
ence and its role in remission and relapse within this popula-
tion. Moreover, we have followed a prevalence cohort,
which incorporates a heterogeneous patient population with
differing disease durations and characteristics. Our epilepsy
syndrome classification is also broad and may include
syndromes with differing outcomes and responses to drugs.
Finally, we relied on patient reports of seizures, which may
be an underestimate of their true seizure frequency.
Throughout this article we have chosen to define remis-
sion as ‡12 or ‡24 months without seizures. Even after such
a remission, there is an extremely high relapse rate. It
appears that after approximately 3 years of seizure remis-
sion, the likelihood of relapse stabilizes at a low rate. Fur-
ther work will be needed to solidify the appropriate time
interval necessary to declare a true remission, analogous to
the cancer literature that has defined remission as a 5-year
period based upon the risk for recurrence. Once further data
are available in adult cohorts with DRE, multicenter studies
can be used to truly identify factors associated with the like-
lihood of a lasting remission in this population.
In conclusion, adult patients with DRE have a cumulative
probability for a 12-month seizure remission of 5% per year
that continues over many years of follow-up. However, this
population also has a high likelihood of relapse, even after
the first year of seizure freedom. Physicians should give
their DRE patients hope that considerable improvement can
be obtained, but they should be cautious when giving a
prognosis for the likelihood of complete seizure remission.
Both the duration of remission and the likelihood of relapse
have serious implications for the lives of these patients, par-
ticularly with respect to when they should be permitted to
resume driving.
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